

New England Consortium Node Newsletter – May 2026

CTN Steering Committee Meeting – April 13–15, 2026



Meeting Highlights & Poster Presentations




CTN Community Representative Council – John Hamilton, LMFT, LADC



The Treatment of Patients with Substance Use Disorders and Co-occurring Mood Disorders (presentation) – Roger D. Weiss, MD



CTN-145 (ENVISION) – Kathryn Hawk, MD



CTN-154 (EMS-BUP) – Edouard Coupet, MD, Gail D'Onofrio, MD, Kathryn Hawk, MD



"CTN-99 Supplement "Racial and Ethnic ED Patient Clinician Concordance in OUD" – Edouard Coupet, MD, Gail D'Onofrio, MD, Kathryn Hawk, MD

Study Updates

CTN-0100 (RDD): Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (NIH HEAL Initiative)

Co-Lead Investigators: **Ned Nunes, Jr, MD, Roger Weiss, MD**

3 sites participating; McLean Hospital-Square Medical Group; SSTAR, Liberation Programs.

Retention Primary Outcome database lock for the NIDA CTN-0100 occurred on Tuesday, April 14, 2026.

Co-Lead Investigators: **R. Kathryn McHugh, PhD, Kathryn Hefner, PhD**

The study is enrolling participants from the CTN-0100 and CTN-0097. A total of 369 participants have been enrolled in the study with 365 from the CTN-0100 RDD study and 4 from CTN-0097. In Year 1, 3,253 monthly assessments were completed; in Year 2, 2,137 monthly assessments have been completed to date; and in Year 3, 421 monthly assessments have been completed to date. The current total rate of overall primary outcome availability is 100%.

CTN-0126 (FORWARD): Longitudinal Follow-Up of Individuals with Opioid Use Disorder

Lead CTN-0146 (APEX): A cohort study of pain, psychological, and drug use outcomes of adolescents after major surgery

Co-Lead Investigators: **Sharon Levy, MD, MPH, Joseph Cravero, MD**

The study has enrolled 3,976 dyads with four sites actively recruiting. The first round of EMR data abstraction has been completed, and QC/QA processes are underway. The study had its 1st DSMB meeting on May 13, 2026 and was recommended to continue. The APEX protocol paper was published in the JSAT CTN 25th anniversary special issue.

Lead CTN-0131 (EMBOSS): Office-Based Methadone versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment

Lead Investigator: **David Feillin, MD**

Co-Lead Investigator: **Paul Joudrey, MD, MPH**

404 participants across the 6 sites have been randomized of the target 600. Provider focus groups for the qualitative implementation sub-study are in the analysis phase, and RCT participant interviews continue. The Extended sub-study continues allowing eligible participants to remain on office-based methadone once they have completed the RCT. The DSMB meeting occurred on May 18, 2026.

Co-Lead Investigators: **Kathryn Hawk, MD, MHS, Gail D'Onofrio, MD, MS, Andrew Herring, MD**

To date, 197 of the proposed 360 have been randomized (55% of proposed). Sites include: Highland Hospital in Oakland, Maine Medical Center, San Leandro Hospital, University of Utah Hospital, Cooper University Hospital in NJ.

Lead CTN-0145 (ENVISION): High vs Standard Buprenorphine ED Initiation

Co-Lead Investigators: **Gail D'Onofrio, MD, MS, Andrew Herring, MD, Gerard Carroll, MD, FAAEM, EMT-P, Nicholas Simpson, MD**

All required local Institutional Review Board (IRB) approvals and Single IRB (SIRB) site approvals have been obtained. One site has started the pilot portion of the trial, and the other two sites are completing the final steps to be endorsed to start recruitment. Participant enrollment will take place across three participating EMS systems: Cooper (Camden, NJ), Alameda (Oakland, CA), and Hennepin (Minneapolis, MN).

Lead CTN-0154: EMS Initiated Buprenorphine for Opioid Use Disorder

Publications



Sharon Levy et al... Node Contributors: Sydney Pierce, Joseph Cravero, Melissa Brogna, Gabriel Brat, Gabriel Hassler, Machiko Minegishi, Griffin Weber, Dinah Sher Gongora, Rose Wosepka, Elissa R. Weitzman. Adolescent outcomes of Post-operative opioid EXposure (APEX): Protocol for a multisite observational study, *Journal of Substance Use and Addiction Treatment*, 2026, 209958, ISSN 2949-8759_ <https://doi.org/10.1016/j.josat.2026.209958>



Laura J. Chavez, et al... Node Contributors: Sarah M. Bagley, Jeffrey H. Samet. Opioid Use Disorder Medications Among Youth in Primary Care: Subgroup Analysis of the PROUD Trial. *Pediatrics Open Science*, April 2025; 1 (2): 1–10. <https://doi.org/10.1542/pedsos.2024-000392>



Gail D'Onofrio, David A Feillin et al... Node Contributors: Andrew A Herring, Kathryn F Hawk, James Dziura, Michael V Pantaloni, Patricia Owens, Shara Martel, Edouard Coupet Jr, E Jennifer Edelman. Emergency Department–Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial. *JAMA*, 2026;335(11):948–960. <https://doi.org/10.1001/jama.2025.27019>



Aimee N.C. Campbell et al... Node Contributors: Dawn E. Sugarman, Shelly F. Greenfield. Gender-specific addiction research needed now more than ever: Reflections from 25 years of the NIDA Clinical Trials Network Gender Special Interest Group. *Journal of Substance Use and Addiction Treatment*, 2025, 209849, ISSN 2949-8759. <https://doi.org/10.1016/j.josat.2025.209849>



Roger D. Weiss et al... Node Contributors: Scott E Provost. Research Ethics in Stopping Opioid Use Disorder Medication. *JAMA Psychiatry*, 2026;83(5):439–440. [doi:10.1001/jamapsychiatry.2026.0246](https://doi.org/10.1001/jamapsychiatry.2026.0246)



Katharine A Bradley et al... Node Contributors: Zoe M. Weinstein, Jeffrey H. Samet. PROUD Trial collaborators on sex, race and ethnicity. Differences in benefits of office based opioid treatment: secondary analyses across sub-groups in the PROUD randomized controlled implementation trial. *Addiction*. 2026;121(3):629–642. [PMCID: PMC12829311](https://pubmed.ncbi.nlm.nih.gov/PMC12829311/)



Edouard Coupet Jr et al... Node Contributors: Marek C. Chawarski, Patricia H. Owens, David A. Feillin, Kathryn F. Hawk, Shara H. Martel, Gail D'Onofrio. “Exploring Preferences in Emergency Department Coordination of Opioid Use Disorder Treatment by Race and Ethnicity.” *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine* vol. 33,2 (2026): e70253. [doi:10.1111/acem.70253](https://doi.org/10.1111/acem.70253)




Edouard Coupet Jr et al... Node Contributors: Marek C. Chawarski, Patricia H. Owens, David A. Feillin, Kathryn F. Hawk, Shara H. Martel, Gail D'Onofrio. Racial and Ethnic Factors and Opioid Use Disorder Treatment After an Emergency Department Visit. *JAMA Netw Open*. 2025;8(7):e2520661. [doi:10.1001/jamanetworkopen.2025.20661](https://doi.org/10.1001/jamanetworkopen.2025.20661)




Kathryn Hawk et al... Node Contributors: Andrew Herring, Marek Chawarski, Shara Martel, Patricia Owens, Gail D'Onofrio. Emergency Department-initiated standard versus high-dose buprenorphine induction (ENVISION): a randomised clinical trial protocol. *BMJ Open* 2026;16:e113762. [doi:10.1136/bmjopen-2025-113762](https://doi.org/10.1136/bmjopen-2025-113762)

NECN members present at CPDD



Shelly Greenfield MD, MPH



Edouard Coupet MD, MS
CTN-0099



Jessica Heil, MS
CTN-0154




Andrew Herring, MD



**CPDD trained therapy llamas
help attendees relieve
stress and enjoy a unique
conference experience!!**



Kathryn Hawk MD, MHS
CTN-0099



Vicknasingam Kasinather BSoc, Sc, MA,
PhD, Marek Chawarski, PhD, Richard
Schottenfeld, MD



Caitlin Ryus, MD, MPH



Ethan Cowan MD &
Kathryn Hawk MD, MHS
CTN-0099